300453 Jiangxi Sanxin Medtec
- 7.74
- -0.19-2.40%
Jiangxi Sanxin Medtec News
Express News | Sanxin Medical: Obtained hemodialysis concentrate medical device registration certificate
Sanxin Medical (300453.SZ) plans to pay 1.5 yuan for 10 shares to be deducted from interest on April 25
Sanxin Medical (300453.SZ) announced that the company's 2023 equity distribution plan: a cash dividend of 1.5 yuan (tax included) will be distributed to all shareholders for every 10 shares; the exclusion date is: April 25, 2024.
Sanxin Medical (300453.SZ): Net profit of 53.618,700 yuan in the first quarter increased 19.72% year-on-year
Gelonghui, April 16, 丨 Sanxin Medical (300453.SZ) released its report for the first quarter of 2024, with operating income of 331 million yuan, up 21.34% year on year; net profit attributable to shareholders of listed companies was 53.618,700 yuan, up 19.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 467.935 million yuan, up 28.61% year on year; basic earnings per share were 0.1032 yuan.
Express News | Sanxin Medical: The company's hemodialysis product collection and bid had little impact on the factory price
Jiangxi Shengdankang, a wholly-owned subsidiary of Sanxin Medical (300453.SZ), received a medical device production license
Sanxin Medical (300453.SZ) announced that Jiangxi Shengdankang Medical Technology Co., Ltd. (“Jiangxi Shengdankang”), a wholly-owned subsidiary of the company, has obtained a “Medical Device Production License” issued by the Jiangxi Drug Administration. According to the announcement, Jiangxi Shengdankang specializes in the development of products related to chronic kidney disease medical equipment, traditional Chinese medicine colon dialysis, traditional Chinese medicine and device combinations, and sales and service of medical device products.
Sanxin Medical (300453.SZ): The products of the holding subsidiary passed the innovative medical device review
Sanxin Medical (300453.SZ) announced that recently, Jiangxi Colectin Biotechnology Co., Ltd. (hereinafter referred to as “colevipid”), a holding subsidiary of the company, received the “Jiangxi Province Class II Medical Device Innovative Product Registration Review Results Form” issued by the Jiangxi Drug Administration. The “Leakage Monitor”, a product independently developed by Colectin, was approved for the registration review of Class II medical device innovation products in Jiangxi Province.
Sanxin Medical (300453) 2023 Report Review: Collection Implementation Accelerates Localization and Focus on Extending the Entire Nephrology Industry Chain
Incident: The company released the 2023 annual report. In 2023, it achieved operating income of 1,300 million yuan, a year-on-year decrease of 2.69%; net profit to mother was 207 million yuan, an increase of 11.92% over the previous year; net profit not attributable to mother1
Sanxin Medical (300453): 2023 performance is in line with expectations, domestic substitution in the hemodialysis industry wants to accelerate
Incident The company released its 2023 annual report. The company achieved total revenue of 1,300 million yuan, a year-on-year decrease of 2.69%, and net profit to mother of 207 million yuan, an increase of 11.92% over the previous year. Among them, blood purification category: 2023
The subsidiary of Sanxin Medical (300453.SZ) Holdings obtained a medical device production license
According to the Zhitong Finance App, Sanxin Medical (300453.SZ) announced that the company's holding subsidiary Jiangxi Colectin Biotechnology Co., Ltd. (“colevipid” for short) has obtained a “Medical Device Production License” issued by the Jiangxi Drug Administration. The acquisition of the “Medical Device Production License” by Colectin is based on actual production and operation needs. It helps the company promote the production and operation of medical devices related to vascular access and peripheral vascular intervention, improves the company's industrial layout, further enhances the company's market competitiveness, and will have a positive impact on the company's future production and operation.
Sanxin Medical (300453): Exceed incentive targets and look forward to breakthroughs in new business areas
Incident: The company released its 2023 annual report, achieving operating income of 1.3 billion yuan (-2.7%), net profit to mother of 210 million yuan (+11.9%), and net profit of 180 million yuan (+8.6%) after deducting non-return to mother. Over-completion of equity
Sanxin Medical (300453.SZ): Net profit for 2023 increased 11.92% to 207 million yuan, and plans to pay 10 to 1.5 yuan
Gelonghui March 22丨Sanxin Healthcare (300453.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,300 million yuan, a year-on-year decrease of 2.69%; net profit attributable to shareholders of listed companies was 207 million yuan, up 11.92% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 181 million yuan, up 8.56% year on year; basic earnings per share was 0.3987 yuan; it plans to distribute a cash dividend of 1.5 yuan (tax included) to all shareholders for every 10 shares.
Sanxin Medical (300453.SZ): 1.60% of shares have been repurchased cumulatively
Gelonghui, March 1, 丨 Sanxin Medical (300453.SZ) announced that as of February 29, 2024, the company had repurchased 8,295,650 shares of the company's shares through a dedicated securities account. The repurchased shares accounted for 1.60% of the company's total share capital. The highest transaction price was 5.60 yuan/share, and the minimum transaction price was 4.90 yuan/share. The repurchase capital had been 43,452,867.60 yuan (not including transaction fees).
Sanxin Medical (300453.SZ): Sichuan Weilisheng passed the high-tech enterprise certification for the first time
Gelonghui, Feb. 19: Sanxin Medical (300453.SZ) announced that its wholly-owned subsidiary, Sichuan Weilisheng Medical Technology Co., Ltd. (“Sichuan Weilisheng”), recently received the “High-tech Enterprise Certificate” jointly issued by the Sichuan Provincial Department of Science and Technology, the Sichuan Provincial Department of Finance, and the Sichuan Taxation Bureau of the State Administration of Taxation, and passed the certification of a high-tech enterprise for the first time.
Sanxin Medtec's Unit Registers Colon Cleansing Device; Shares Up 3%
Jiangxi Sanxin Medtec's (SHE:300453) subsidiary, Jiangxi Shengdankang Medical Technology, obtained a medical device registration certificate for its intestinal hydrotherapy machine. The device is used
Sanxin Medical (300453.SZ): Intestinal hydrotherapy machine obtained medical device registration certificate
Zhitong Finance App News, Sanxin Medical (300453.SZ) announced that Jiangxi Shengdankang Medical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently obtained the “Medical Device Registration Certificate” issued by the Jiangxi Drug Administration. The product name is an intestinal hydrotherapy machine, which is mainly used for colon cleansing.
Sanxin Medical (300453.SZ): 1.58% of shares have been repurchased cumulatively
Gelonghui, Feb. 7, 丨 Sanxin Medical (300453.SZ) announced that as of February 7, 2024, the company had repurchased 8,195,650 shares of the company's shares through a dedicated securities account, accounting for 1.58% of the company's current total share capital (519,596,545 shares). The highest transaction price of the repurchase was 5.60 yuan/share, and the minimum transaction price was RMB 4.90 yuan/share, and the total transaction amount was RMB 42.9569 million (excluding transaction fees).
Sanxin Medical (300453.SZ) obtained vascular sheath medical device registration certificate
Sanxin Medical (300453.SZ) issued an announcement that Jiangxi Colectin Biotechnology Co., Ltd., a wholly-owned subsidiary of the company,...
Express News | The 12-day stock market reached a record high, and the Agricultural Bank of China and the Bank of China both rewrote history
Express News | Sanxin Medical: Plans to buy back shares for 30 million yuan to 60 million yuan
Sanxin Medical (300453.SZ) obtained a medical device registration certificate for single-use sterile anti-acupuncture needles
Sanxin Medical (300453.SZ) announced that the company recently obtained “Medical Devices...” issued by the State Drug Administration
Analysis
Price Target
No Data
